TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05879484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valemetostat
Description: Phase Ib: Valemetostat will be given orally every day of every cycle (DL-1: 100mg, DL1: 150mg, DL2: 200mg).~Phase II: Valemetostat will be given orally daily at the recommended phase 2 dose.
Study: NCT04577300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501
Description: Implant of Neurotech NT-501 device(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501
Description: Implant of Neurotech NT-501 device(s)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Sham implantation
Study: NCT04734418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Intravenous pump injection.The initial dose of remifentanil is 0.05 μg/kg/min.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of remifentanil is 0.12 μg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous pump injection.The initial dose of dexmedetomidine is 0.5 μg/kg/h.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of dexmedetomidine is 1.0 μg/kg/h.
Study: NCT05128513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DELP
Description: The blood was pumped into the PCS2 plasma separator through one side of the forearm vein. The plasma was separated by pump and then sent to the DELP system (Shanghai Jiangxia Blood Technology Co.). After purification, the plasma was returned to the patient via another forearm vein. The total treatment plasma volume was 800-1,000 mL; the anticoagulant 4% sodium citrate dehydrate solution with a ratio of 1:16 to plasma, was dropped before pumping. To prevent hypocalcemia, 500 mg CaCl2 diluted with 250 mL physiological saline was infused at a rate of 150 mL/h, in the first cycle of the returning blood transfusion.
Study: NCT04691141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-016
Description: 59 patients enrolled will be treated with ATG-016, orally, each 4 week (28-day) a cycle
Study: NCT04851119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegavivint
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study: NCT06517251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm-hand BOOST
Description: Aha BOOST consists of 20 one-hour BOOST sessions (spread over 4 weeks, 5 days a week) and one hour of individual technology-supported therapy per week (divided in two times 30 minutes), with the aim to provide intensive, goal-oriented upper limb therapy. The sessions will be executed with a maximum of two participants, under supervision of a trained therapist.~The group sessions are focused on four key aspects: neurophysiology, sequences of reaching and grasping, de-weighting of the arm, and orientation of the hand towards objects. The different exercises are tailored to the individual patient, based upon ongoing assessment, discussion within the group of therapists, and individual treatment goals of the patient. Additionally, patients exercise two times 30 minutes per week with the AMADEO® (Tyromotion, Austria), an upper limb robotic device, focusing on finger and hand rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower limb BOOST
Description: L-BOOST consists of 20 one-hour sessions and a personalized two times 30 minutes self-exercise program per week and focused on strengthening exercises for the lower limbs and general reconditioning. During the group sessions, circuit-class training is performed according to a standardized written protocol: 20 minutes of cycling on a sitting bike, 20 minutes of strengthening exercises for muscles around hip and knee (e.g. sit-to-stand training), 10 minutes of knee exercises using quadriceps bench in free swing mode and 10 minutes of leg press exercises. Again, a gradual increase in levels of difficulty is provided. Additionally, each patient receives a self-exercise program (balance; strengthening of foot, knee, and hip muscles; walking exercises), which is executed two times 30 minutes per week under minimal supervision of a therapist. None of the exercises involve the use of the upper limb.
Study: NCT06238843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: Subjects in the contral arm will receive irinotecan 125mg/m2 IV D1, D8, Q3W in 3-weeks cycles or 150mg/m2 IV D1, Q2W in 2-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI343
Description: IBI343: Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Subjects in the contral arm will receive paclitaxel 80mg/m2 IV D1, D8, D15, Q4W in 4-week cycles.
Study: NCT05840952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558
Description: single or multiple doses of ALG-097558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558
Description: single or multiple doses of ALG-097558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558
Description: single or multiple doses of ALG-097558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558
Description: single or multiple doses of ALG-097558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single or multiple doses of placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single or multiple doses of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Multiple doses of Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Multiple doses of Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Multiple doses of Carbamazepine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558 in solution formulation
Description: ALG-097558 in solution administered in fasted state
Study: NCT05675410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT05840952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-097558 in tablet formulation
Description: ALG-097558 in tablet administered in fasted and fed state
Study: NCT05666492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Platelet-rich plasma will be placed on the olfactory epithelium topically.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Platelet-rich plasma will be placed on the olfactory epithelium topically.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be placed on the olfactory epithelium topically.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be placed on the olfactory epithelium topically.
Study: NCT06289491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent
Description: Patients will have a Hydrus Microstent inserted into the canal of Schlemm at the time of cataract surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incisional goniotomy
Description: Patients will have incisional goniotomy to open the trabecular meshwork with a Sinskey hook at the time of cataract surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excisional goniotomy
Description: Patients will have excisional goniotomy to remove the trabecular meshwork with a Kahook Dual Blade at the time of cataract surgery
Study: NCT04677374

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care referral approach which is a brief health talk conducted once every morning by a VMMC mobilizer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified Health Education
Description: More detailed health talk conducted during each group health talk session by the VMMC mobilizer and champions describing VMMC, its benefits and how to access the service and testimonies from men who have successfully undergone VMMC

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS/telephonic Tracing
Description: SMS tracing to remind participants of VMMC appointments

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transportation Reimbursement
Description: Transportation reimbursement to offset the cost of transportation for VMMC appointments
Study: NCT04998474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FRAME-001 personalized vaccine
Description: Patients will receive personalized peptide vaccine FRAME-001 based on frame-shift mutations (Frames) detected by Whole Genome Sequencing (WGS)/Ribonucleic Acid sequencing (RNAseq) in a tumor biopsy. FRAME-001 vaccine will be administered in four sequential cycles at 3-week interval (Q3W), along standard maintenance monotherapy of pembrolizumab (administration Q3W or Q6W). Each cycle will be consisting of up to four subcutaneous injections at up to four different sites in the upper and lower limbs.
Study: NCT05675410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV
Study: NCT06026761

Intervention type: DEVICE
Intervention: Skiin garment and pods
Description: Participants will be asked to wear two pieces of equipment to record physiological data:~1. A Skiin garment that contains IMU and ECG sensors~2. A Cosmed K5 metabolic cart that will record breathing rate data~Participants will then be asked to perform various tasks of daily living (e.g. watching TV, sweeping the floor), general strength exercises (e.g. squats, triceps dips, lunges), and aerobic exercises (e.g. walking, running) as instructed by researchers
Study: NCT05238142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed™ 780G Insulin Pump system
Description: MiniMed 780G insulin pump with Guardian 4 sensor (phase 1) MiniMed™ 780G BLE 2.0 insulin pump used in combination with Disposable Sensor 5 (phase 2)
Study: NCT04956731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Provision of Medication Abortion
Description: Pharmacists providing start to finish medication abortions
Study: NCT05675410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV
Study: NCT05448833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-LAP™ SYSTEM
Description: Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
Study: NCT06438471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC5026 oral tablet
Description: There will be two ascending dose regimens of EC5026, which will be administered over two consecutive Treatment Periods. During each Treatment Period, EC5026 will be administered orally once daily for 7 consecutive days, with a loading dose on Day 1 and a maintenance dose on Days 2-7 of each treatment period. All study subjects will be enrolled in both Treatment Periods and will receive both dose regimens consecutively, for a total duration of 14 days.~Oral doses of EC5026 tested in each Treatment Period:~Treatment Period 1: 6 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 Treatment Period 2: 8 mg loading dose on Day 8 / 4 mg Maintenance dose on Days 9-14
Study: NCT05675410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Study: NCT06438471

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Participants will be administered a matching oral placebo for 14 consecutive days.
Study: NCT06035575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Development of the original video used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script will typically be shown to the patient within 48-72 hours of the acute care visit, with a maximum window of 5 days post visit.
Study: NCT06285201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T
Description: 8 mg/kg IV of Test drug manufactured by I-Mab Biopharma(Hangzhou)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T
Description: 8 mg/kg IV of Test drug manufactured by I-Mab Biopharma(Hangzhou)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R
Description: 8 mg/kg IV of Test drug manufactured by Patheon Italia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R
Description: 8 mg/kg IV of Test drug manufactured by Patheon Italia
Study: NCT06104488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle
Study: NCT05945602

Intervention type: OTHER
Intervention: Neurophysiologic Biomarker Assessments
Description: Non-invasive electroencephalography will be recorded to derive neurophysiologic biomarkers.

Intervention type: OTHER
Intervention: Neurophysiologic Biomarker Assessments
Description: Non-invasive electroencephalography will be recorded to derive neurophysiologic biomarkers.

Intervention type: OTHER
Intervention: Neurophysiologic Biomarker Assessments
Description: Non-invasive electroencephalography will be recorded to derive neurophysiologic biomarkers.
Study: NCT05658627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active release technique
Description: Hamstring active release technique-

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: ultrasound therapy - stretching Exercise - Strengthening Exercise -

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: ultrasound therapy - stretching Exercise - Strengthening Exercise -
Study: NCT06481371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zuojinwan
Description: In the Chinese medicine combination group, 3g of Zuojinwan was added to the western medicine group twice a day for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium enteric-coated tablets
Description: For epigastric pain syndrome

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium enteric-coated tablets
Description: For epigastric pain syndrome

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mosapride citrate
Description: Postprandial discomfort syndrome

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mosapride citrate
Description: Postprandial discomfort syndrome
Study: NCT05962632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride based varnish (Dentkist Charm Fill Varnish )
Description: topical Fluoride varnish administrated professionally every 3 months in the clinic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pro care gel remineralizing agent
Description: topical remineralizing agent (Surface Pre-Reacted Glass ionomer filler SPRG based)SHOFU company

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: examine the impact of Mobile application on caries prevention

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: tooth brushing/fluoridated toothpaste over the counter 1450 ppm, interdental cleaning,fluoride rinse OTC
Description: interdental cleaning(dental floss),fluoride rinse OTC (B-FRESH MOUTH WASH )
Study: NCT05846880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: For first three cycles, taken orally once daily for 28 days at 10mg/day dose. After cycle 4, taken orally once daily at 15 mg/day dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: For first three cycles, taken orally once daily for 28 days at 10mg/day dose. After cycle 4, taken orally once daily at 15 mg/day dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance Vitamin D
Description: After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, will start maintenance therapy with Monthly replacement with 50,000 IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No maintenance Vitamin D
Description: After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, stop replacement and continue monitoring levels
Study: NCT05058612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: 10 mg PO/NG q8h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose PO/NG 18h
Study: NCT05858450

Intervention type: BIOLOGICAL
Intervention: Comirnaty
Description: COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.

Intervention type: BIOLOGICAL
Intervention: Comirnaty
Description: COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Study: NCT05675410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO
Study: NCT05531760

Intervention type: PROCEDURE
Intervention: Descemet Membrane Endothelial Keratoplasty
Description: DMEK-operated eyes

Intervention type: PROCEDURE
Intervention: Descemet Membrane Endothelial Keratoplasty
Description: DMEK-operated eyes
Study: NCT05675410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT05694871

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo a CT Scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT Scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen collection
Description: Undergo blood sample collection